IL24 and cancer: In summary, the significant CaP antitumor effects observed following combination treatment with Ad.tCCN1-CTV-m7 + BI-97D6 is a summation of multiple independent biological attributes of these agents including: a) cancer-selective oncolytic activity mediated by Ad.tCCN1-CTV-m7; b) cancer-selective antitumor effects mediated by both Ad.tCCN1-CTV-m7 and BI-97D6; and c) ‘bystander effects’ mediated by Ad.tCCN1-CTV-m7 through production and the secretion of MDA-7/IL-24 protein.